**Name of Journal: *World Journal of Biological Chemistry***

**Manuscript No: 20018**

**Manuscript Type: Original Article**

***Basic Study***

**JAK3 inhibitor VI is a mutant specific inhibitor for epidermal growth factor receptor with the gatekeeper mutation T790M**

Nishiya N *et al*. JAK3 inhibitor inhibits EGFR T790M

**Naoyuki Nishiya, Yasumitsu Sakamoto, Yusuke Oku, Takamasa Nonaka, Yoshimasa Uehara**

**Naoyuki Nishiya, Yusuke Oku, Yoshimasa Uehara,** Department of Microbial Chemical Biology and Drug Discovery, Iwate Medical University School of Pharmacy, Yahaba, Iwate 028-3694, Japan

**Yasumitsu Sakamoto, Takamasa Nonaka,** Department of Structural Biology and Biophysics, Iwate Medical University School of Pharmacy, Yahaba, Iwate 028-3694, Japan

**Author contributions:** Nishiya N, NonakaT, and Uehara Y designed the research; Nishiya N and Sakamoto Y performed the research; NishiyaN, SakamotoY, and OkuY analyzed the data; and Nishiya N and Sakamoto Y wrote the paper.

**Conflict-of-interest statement:** None of the authors have financial conflicts related to this work.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to: Naoyuki Nishiya, PhD,** Department of Microbial Chemical Biology and Drug Discovery, Iwate Medical University School of Pharmacy, 2-1-1 Nishitokuta, Yahaba-cho, Shiwa-gun, Iwate 028-3694, Japan. [nnishiya@iwate-med.ac.jp](mailto:nnishiya@iwate-med.ac.jp)

**Telephone:** +81-19-6515111

**Fax:** +81-19-6981841

**Received:** May 27, 2015

**Peer-review started:** May 30, 2015

**First decision:** June 18, 2015

**Revised:** July 22, 2015

**Accepted:** September 10, 2015

**Article in press:**

**Published online:**

**Abstract**

**AIM:** To identify non-quinazoline kinase inhibitors effective against drug resistant mutants of epidermal growth factor receptor (EGFR).

**METHODS:** A kinase inhibitor library was subjected to screening for specific inhibition pertaining to the *in vitro* kinase activation of EGFR with the gatekeeper mutation T790M, which is resistant to small molecular weight tyrosine kinase inhibitors (TKIs) for EGFR in non-small cell lung cancers (NSCLCs). This inhibitory effect was confirmed by measuring autophosphorylation of EGFR T790M/L858R in NCI-H1975 cells, an NSCLC cell line harboring the gatekeeper mutation. The effects of a candidate compound, Janus kinase 3 (JAK3) inhibitor VI, on cell proliferation were evaluated using the MTT assay and were compared between T790M-positive and -negative lung cancer cell lines. JAK3 inhibitor VI was modeled into the ATP-binding pocket of EGFR T790M/L858R. Potential physical interactions between the compound and kinase domains of wild-type (WT) or mutant EGFRs or JAK3 were estimated by calculating binding energy. The gatekeeper residues of EGFRs and JAKs were aligned to discuss the similarities among EGFR T790M and JAKs.

**RESULTS:** We found that JAK3 inhibitor VI, a known inhibitor for JAK3 tyrosine kinase, selectively inhibits EGFR T790M/L858R, but has weaker inhibitory effects on the WT EGFR *in vitro*. JAK3 inhibitor VI also specifically reduced autophosphorylation of EGFR T790M/L858R in NCI-H1975 cells upon EGF stimulation, but did not show the inhibitory effect on WT EGFR in A431 cells. Furthermore, JAK3 inhibitor VI suppressed the proliferation of NCI-H1975 cells, but showed limited inhibitory effects on the WT EGFR-expressing cell lines A431 and A549. A docking simulation between JAK3 inhibitor VI and the ATP-binding pocket of EGFR T790M/L858R predicted a potential binding status with hydrogen bonds. Estimated binding energy of JAK3 inhibitor VI to EGFR T790M/L858R was more stable than its binding energy to the WT EGFR. Amino acid sequence alignments revealed that the gatekeeper residues of JAK family kinases are methionine in WT, similar to EGFR T790M, suggesting that TKIs for JAKs may also be effective for EGFR T790M.

**CONCLUSION:** Our findings demonstrate that JAK3 inhibitor VI is a gatekeeper mutant selective TKI and offer a strategy to search for new EGFR T790M inhibitors.

**Key words:** Epidermal growth factor receptor; Tyrosine kinase inhibitor; Gatekeeper mutation; Non-small cell lung cancers

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Non-small cell lung cancers caused by mutations in the epidermal growth factor receptor (EGFR) initially respond to tyrosine kinase inhibitors (TKIs). However, the therapeutic efficacy of EGFR-TKIs is limited by drug-resistant mutations such as the gatekeeper mutation T790M. Our present study rediscovered JAK3 inhibitor VI, a known TKI for Janus kinases (JAKs), as a selective EGFR T790M inhibitor. Our structural analysis revealed similarities among EGFR T790M and JAKs, offering a possible strategy to search for EGFR T790M inhibitors from known kinase inhibitors. Repositioning of the existing therapeutics may facilitate solving clinical problems such as drug resistance and toxicity.

Nishiya N, Sakamoto Y, Oku Y, Nonaka T, Uehara Y. JAK3 inhibitor VI is a mutant specific inhibitor for epidermal growth factor receptor with the gatekeeper mutation T790M. *World J Biol Chem* 2015; In press

**INTRODUCTION**

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib and erlotinib are clinical therapeutics effective on non-small cell lung cancers (NSCLCs) with activating mutation in EGFR[1,2]. Most frequent activating mutations in EGFR, a point mutation L858R and an exon19 deletion (delE746-A750), increase affinity for EGFR-TKIs relative to that for wild type (WT)[3,4]. However, the development of drug-resistant mutations such as the gatekeeper mutation T790M limits clinical efficacies of the EGFR-TKIs and is the major cause of acquired resistance in NSCLC patients[5,6].

An irreversible EGFR-TKI with a reactive acceptor group covalently binds to a conserved cysteine residue in the EGFR kinase domain (Cys 797) *via* a Michael addition reaction. The covalent bond formation increases stability of the complex formation between a TKI and the ATP-binding site of the kinase domain in comparison with reversible inhibitors. Therefore, irreversible EGFR-TKIs provide the ability to inhibit EGFR T790M[7-12]. However, EGFR T790M inhibition by the quinazoline-based irreversible TKIs causes simultaneous inhibition of the WT EGFR because of similar ATP affinity between WT and the T790M mutant, resulting in adverse effects such as skin rash and diarrhea. Therefore, the use of irreversible EGFR-TKIs has been limited in gefitinib- or erlotinib-resistant NSCLCs and by the dose-limiting toxicity[13,14].

Here we report that Janus kinase 3 (JAK3) inhibitor VI [15], a known TKI for a tyrosine kinase JAK3, selectively inhibits EGFR T790M/L858R, but has less inhibitory effect on the WT EGFR *in vitro*. JAK3 inhibitor VI also suppresses the proliferation of NCI-H1975 cells, an NSCLC cell line harboring EGFR T790M/L858R. This inhibitor is modeled into the ATP-binding pocket of EGFR T790M/L858R and forms potential hydrogen bonds with the kinase domain of EGFR T790M/L858R. The gatekeeper residue of JAK3 is methionine in WT, and the overall structure of the catalytic domain of JAK3 is closely related to that of EGFR. Our findings indicate that a JAK3 inhibitor is a mutant-selective reversible TKI for EGFR T790M.

**MATERIALS AND METHODS**

***Reagents and cell lines***

JAK3 inhibitor VI and JAK inhibitor I were purchased from Calbiochem (San Diego, CA). Gefitinib was purchased from JS Research Chemical Trading (Wedel, Germany). SCADS inhibitor kit 3 was provided by Screening Committee of Anticancer Drugs supported by a Grant-in-Aid for Scientific Research on Priority Area “Cancer” from The Ministry of Education, Culture, Sports, Science and Technology, Japan. Antibodies against EGFR, pEGFR (Y1045), pEGFR (Y1068), and STAT3 were purchased from Cell Signaling Technology (Beverly, MA). Anti-pSTAT3 (Y705) was purchased from BD (Franklin Lakes, NJ). HRP-conjugated anti-phosphotyrosine antibodies PY20 and 4G10 were purchased from BD and Millipore (Billerica, MA). NCI-H1975 cell line was obtained from the American Type Culture Collection and cultured in Dulbecco’s modified Eagle’s medium supplemented with 2 mmol/L L-glutamine and 10% Fetal Bovine Serum at 37 ℃ in a humidified atmosphere of 5% CO2.

***In vitro kinase assay and screening for kinase inhibitors***

One hundred nanograms of recombinant cytoplasmic domains (amino acid residues 696 to the C-terminus) of the WT EGFR, L858R, or T790M/L858R (Cell Signaling Technology) were preincubated with kinase inhibitors in 25 μL of kinase reaction buffer (120 mmol/L HEPES, pH 7.5; 10 mmol/L MgCl2; 10 mmol/L MnCl2; 6 μmol/L Na3VO4; and 2.5 mmol/L DTT) at 25 ℃ for 30 min. Subsequently, 25 μL of ATP/substrate solution containing 2 or 6 μmol/L ATP and 6 μmol/L poly (Glu-Tyr) biotinylated peptide (Cell Signaling Technology) was added to the preincubation mixture. The kinase reaction was performed at 25°C for 30 min and terminated by adding 50 μL of stop buffer (50 mmol/L EDTA, pH = 8.0). Kinase activity was estimated using ELISA with avidin-coated 96-well plates and anti-phosphotyrosine antibodies (PY20 and 4G10).

***Phosphorylation analysis***

NCI-H1975 or A431 cells were pretreated using JAK3 inhibitor VI for 1 h in 0.2% serum conditions and were stimulated using 200 ng/mL EGF for 15 min. Alternatively, NCI-H1975 cells were treated with kinase inhibitors at the indicated concentration for 16 h. Cells were lysed in RIPA buffer (50 mmol/L Tris–HCl, pH = 7.4; 150 mmol/L NaCl; 1% Triton X-100; 1% sodium deoxycholate; 0.1% SDS; 1 mmol/L NaF; 1 mmol/L Na3VO4; and protease inhibitors) and cleared by centrifugation. SDS sample buffer was added to the supernatants. Protein samples were separated using SDS-PAGE and analyzed using Western blotting with antibodies against phospho-specific or total proteins.

***Proliferation* assay**

Cells were cultivated in a flat-bottomed 96-well plate at 1 × 104 cells per well in 150 µL media containing various concentrations of kinase inhibitors for 72 h. The inhibitor-treated cells were incubated in the presence of 0.5 mg/mL 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) in a CO2 incubator for 4 h. One hundred microliters of 20% SDS was added to each well for dissolving the insoluble purple formazan product into a colored solution. The absorption at 570 nm was measured using a spectrophotometer. The means of data values from at least three independent experiments were calculated.

***Docking model analysis***

All starting templates, except the WT EGFR, were prepared by superimposing the crystal structure of the WT EGFR (PDB ID: 4WKQ) onto crystal structures of EGFR-LRTM (PDB ID: 4I22) and JAK3 (PDB ID: 3LXL) without ligands. Docking studies were performed to analyze interactions of some inhibitors in the binding site of the WT EGFR, EGFR-TMLR, and JAK3 through PyRx[16] using AutoDock 4.2.6[17]. The adopted standard protein preparation protocol involves the addition of missing hydrogen atoms to the starting template and the assignment of an ionizable state to each charged group. The docking grid of 11 Å × 12 Å × 14 Å was generated based on the observed binding site of the WT EGFR using gefitinib (PDB ID: 4WKQ). Schematic representations were generated using the UCSF Chimera package[18].

***Statistical analysis***

All data are presented as the mean ± SE. The Mann–Whitney U-test was used to determine statistically significant differences.

**RESULTS**

To profile sensitivities of EGFR mutants against different classes of kinase inhibitors, we assayed *in vitro* recombinant cytoplasmic domains of the WT EGFR, EGFR L858R, or EGFR T790M/L858R for 95 kinase inhibitors (Table 1). Several compounds such as Ellagic acid, Damnacanthal, and RAF1 kinase inhibitor I inhibited all three EGFR kinases activity, but other kinase inhibitors showed selectivity in their inhibitory activity against WT or mutant kinases. Among inhibitors with selectivity, JAK3 inhibitor VI[15] and Gö7874[19] reduced kinase activity of EGFR T790M/L858R. Gö7874 is a known PKC inhibitor and has an indolocarbazole structure that is also seen in staurosporine, a classical kinase inhibitor (Figure 1B). Because it has been reported that indolocarbazole compounds selectively inhibit EGFR T790M but show limited effects on the WT EGFR[20], JAK3 inhibitor VI was used in further studies. JAK3 inhibitor VI, a 3′-pyridyl oxindole compound (Figure 1A), inhibited EGFR T790M/L858R (IC50 = 1.43 μmol/L) mutant, but weaker effects were observed on the L858R mutant (IC50 > 10 μmol/L) and WT EGFR (IC50 > 10 μmol/L) (Figure 1C).

Next, we tested whether JAK3 inhibitor VI decreased EGFR signaling in the EGFR T790M/L858R-positive NCI-H1975 cells. EGF-induced EGFR autophosphorylation at Y1045 was significantly reduced in 10 or 5 μmol/L JAK3 inhibitor VI-treated NCI-H1975 cells (Figure 2A). In contrast, JAK3 inhibitor VI had no effect on the WT EGFR Y1045 phosphorylation in A431 cells (Figure 2B). These data confirm the mutant EGFR-specific blockage by JAK3 inhibitor VI in the T790M/L858R positive NCI-H1975 cells.

Although JAK 3 inhibitor VI specifically inhibited EGFR T790M/L858R in cells, it was not clear whether the T790M/L858R inhibition was a direct effect on the EGFR kinase or an indirect effect *via* JAK3 inhibition. To clarify this point, we analyzed phosphorylation levels of STAT3, a direct JAK3 substrate. The STAT3 phosphorylation level was unchanged even after stimulation using 200 ng/mL EGF, which efficiently elevated EGFR Y1045 phosphorylation (Figures 2A and C). In addition to the effects of JAK3 inhibitor VI on the EGF-stimulated phosphorylation of EGFR T790M/L858R, those on the basal phosphorylation of EGFR T790M/L858R and STAT3 were analyzed pertaining to NCI-H1975 cells in a 10% serum culture condition. In contrast to a decrease in the phosphorylation level of EGFR T790M/L858R at 5 μmol/L JAK3 inhibitor VI, STAT3 Y705 phosphorylation was apparent at 5 µM and began to decrease from a higher concentration, 10 μmol/L (Figure 2D). Another JAK inhibitor, JAK inhibitor I, significantly reduced STAT3 Y705 phosphorylation at 2.5 μmol/L, but did not affect EGFR Y1068 phosphorylation at higher concentrations such as 5 or 10 μmol/L (Figure 2D). These data suggest that JAK3 inhibitor VI reduces the phosphorylation level of EGFR T790M/L858R without JAK3 inhibition, and that JAKs are not major contributors to EGFR phosphorylation in NCI-H1975 cells.

Next, we performed MTT assays to test the effects of JAK3 inhibitor VI on proliferation of EGFR T790M/L858R positive NCI-H1975 cells. NCI-H1975 cells were cultured in 96-well plates for 3 d with or without different concentrations of compounds. JAK3 inhibitor VI showed growth suppression at 10 and 30 μmol/L, but gefitinib or JAK inhibitor I did not (Figure 3A). The effects of JAK3 inhibitor VI on proliferation of the WT EGFR expressing A431 (Figure 3B) and A549 (Figure 3C) cells were also analyzed. These cells were less sensitive to JAK3 inhibitor VI than NCI-H1975 cells.

To obtain structural insight, docking simulations between JAK3 inhibitor VI and kinases were performed. In the model structure, JAK3 inhibitor VI bound to the ATP-binding pocket of EGFR T790M/L858R and formed hydrogen bonds with M793 and T854 residues (Figure 4A). Estimated binding to EGFR T790M/L858R was more stable than that to the WT EGFR and was equivalent with that to JAK3 (EGFR T790M/L858R: -7.38 kcal/mol; JAK3: -7.59 kcal/mol; WT EGFR: -6.23 kcal/mol). Amino acid sequence alignments of the EGFR T790 flanking regions and the corresponding regions of JAKs revealed that the gatekeeper residues of WT JAKs are methionine, similar to those of EGFR T790M (Figure 4B).

**DISCUSSION**

EGFR T790M limits the clinical efficacy of EGFR-TKIs. Irreversible TKIs for EGFR T790M are associated with toxic effects due to simultaneous inhibition of the WT EGFR. In the present study, we found that JAK3 inhibitor VI selectively inhibits EGFR T790M/L858R and had a lesser inhibitory effect on the WT EGFR *in vitro*. JAK3 inhibitor VI also suppressed the proliferation of NCI-H1975 cells harboring EGFR T790M/L858R. Thus, our findings demonstrate that a JAK3 inhibitor is a mutant selective TKI for EGFR T790M/L858R and offer a potential strategy to develop EGFR T790M-specific inhibitors by applying known inhibitors for JAK family kinases closely related to the ErbB family.

JAK3 inhibitor VI selectively inhibits the gefitinib-resistant EGFR T790ML858R. JAK3 inhibitor VI (10 μmol/L) inhibited kinase activity of EGFR T790M/L858R; however, it was ineffective on the activity of the WT EGFR *in vitro* kinase assay (Figure 1C). Furthermore, JAK3 inhibitor VI efficiently reduced autophosphorylation of EGFR T790M/L858R in gefitinib-resistant lung cancer cells, NCI-H1975 (Figure 2A), in contrast to resistance of the WT EGFR in A431 cells (Figure 2B). Dosage restriction of quinazoline-based EGFR-TKI treatments is attributable to the toxicity derived from simultaneous inhibition of the WT EGFR. As a possible solution for the issue, Zhou *et al*[21] reported that compounds with a non-quinazoline structure, pyrimidine, were specifically effective on mutant EGFRs. Staurosporine-related indolocarbazole compounds such as Gö6976 and PKC412 are also more selective for EGFR T790M than quinazoline-based EGFR inhibitors[19]. Therefore, applications of non-quinazoline compounds can confer T790M mutant specific inhibition without affecting the WT EGFR. Our data indicate that JAK3 inhibitor VI, an indol-based compound, provides an additional example of EGFR T790M-specific structures.

JAK3 inhibitor VI suppresses proliferation of NSCLCs harboring the gatekeeper mutation EGFR T790M. EGFR T790M/L858R-expressing NCI-H1975 cells showed reduced proliferation in the presence of JAK3 inhibitor VI, but not in the presence of gefitinib or JAK inhibitor I (Figure 3A). Furthermore, WT EGFR-expressing cell lines, A431 and A549, were less sensitive to JAK3 inhibitor VI in comparison with NCI-H1975 cells (Figures 3B and C), suggesting specific inhibition of EGFR T790M by JAK3 inhibitor VI. Because JAK3 inhibitors block JAK3 that may phosphorylate EGFR, indirect effects *via* JAK3 inhibition may cause a reduction in autophosphorylation of EGFR T790M/L858R in NCI-H1975 cells. However, EGFR T790M/L858R inhibition was observed in lower concentrations of JAK3 inhibitor VI than those of JAK3 inhibition. Another JAK inhibitor, JAK inhibitor I, did not show EGFR T790M/L858R inhibition. Furthermore, T790M kinase inhibition was observed in an *in vitro* assay using recombinant kinases. Therefore, the decrease in autophosphorylation of EGFR T790M/L858R seems to be caused by direct inhibition in EGFR T790M/L858R rather than by JAK3 inhibition-mediated indirect effects.

Structural characteristics of EGFR T790M mutants may be analogous to those of JAK3. In the docking study, JAK3 inhibitor VI bound to the ATP-binding pocket of EGFR T790M/L858R with an additional hydrogen bond (Figure 4A). Binding energy calculations predicted that JAK3 inhibitor VI would more stably bind to EGFR T790M/L858R than to the WT EGFR with an equivalent stability to the simulated binding to JAK3 (Figure 4A). Furthermore, EGFR and JAK family kinases are located in neighboring clans in the human kinome[22], indicating that overall structures of the catalytic domains of JAKs are closely related to those of EGFRs. The gatekeeper residues of WT JAKs are methionines, which are identical to the gatekeeper mutant EGFR T790M (Figure 4B). Sequence alignments of the gatekeeper flanking regions between BCR-ABLs and Aurora kinases indicated that the corresponding residues in Aurora kinases are isoleucines, similar to the gatekeeper mutation T315I. These findings suggest a hypothesis in which inhibitor sensitive kinases such as EGFR L858R, exon19-deleted EGFR, and BCR-ABL obtained structural similarities to other kinases during acquisition of drug resistance. In fact, Aurora kinase inhibitors are effective on BCR-ABL T315I[23,24] in addition to our findings of JAK3 inhibitor VI as an EGFR T790M inhibitor. Therefore, it may be a rational strategy to screen compounds effective on different kinases structurally similar to gatekeeper mutants in the fight against drug resistant kinases.

**ACKNOWLEDGEMENTS**

We thank the Screening Committee of Anticancer Drugs in the Scientific Support Programs for Cancer Research Grant-in-Aid for Scientific Research on Innovative Areas from the Ministry of Education, Culture, Sports, Science and Technology for SCADS inhibitor kits and Chie Ishikawa and Emi Takahashi for technical assistance. None of the authors have financial conflicts related to this work.

**COMMENTS**

***Background***

Tyrosine kinase inhibitors against the epidermal growth factor receptor (EGFR-TKIs) are initially effective on non-small cell lung cancers (NACLCs) caused by EGFR mutations. However, drug-resistant mutations such as the gatekeeper mutation T790M limit the clinical efficacy of EGFR-TKIs.

***Research frontiers***

Irreversible EGFR-TKIs that covalently bind to the EGFR kinase domain have provided a way to inhibit the gatekeeper mutant EGFR T790M.

***Innovations and breakthroughs***

EGFR T790M inhibition by the quinazoline-based irreversible TKIs causes simultaneous inhibition of the WT EGFR, resulting in adverse effects such as skin rash and diarrhea. Our present study rediscovered Janus kinases 3 (JAK3) inhibitor VI as a reversible EGFR-TKI selective for EGFR T790M.

***Applications***

Our structural analysis revealed similarities among EGFR T790M and Janus kinases (JAKs). This may offer a new strategy to screen for EGFR T790M inhibitors from known kinase inhibitors.

***Terminology***

JAKs are protein tyrosine kinases, whose catalytic domain structures are closely related to those of EGFRs.

***Peer-review***

In current manuscript entitled “JAK3 inhibitor VI is a mutant specific inhibitor for EGFR with gatekeeper mutation T790M”, the authors demonstrated that JAK3 inhibitor VI could specifically inhibit EGFR gatekeeper mutation (T790M) in non-small cell lung cancers.

**REFERENCES**

1 **Mok TS**, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med* 2009; **361**: 947-957 [PMID: 19692680 DOI: 10.1056/NEJMoa0810699]

2 **Rosell R**, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sánchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M. Screening for epidermal growth factor receptor mutations in lung cancer. *N Engl J Med* 2009; **361**: 958-967 [PMID: 19692684 DOI: 10.1056/NEJMoa0904554]

3 **Yun CH**, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M, Eck MJ. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. *Cancer Cell* 2007; **11**: 217-227 [PMID: 17349580 DOI: 10.1016/j.ccr.2006.12.017]

4 **Carey KD**, Garton AJ, Romero MS, Kahler J, Thomson S, Ross S, Park F, Haley JD, Gibson N, Sliwkowski MX. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. *Cancer Res* 2006; **66**: 8163-8171 [PMID: 16912195 DOI: 10.1158/0008-5472.CAN-06-0453]

5 **Pao W**, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. *PLoS Med* 2005; **2**: e73 [PMID: 15737014 DOI: 10.1371/journal.pmed.0020073]

6 **Kobayashi S**, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2005; **352**: 786-792 [PMID: 15728811 DOI: 10.1056/NEJMoa044238]

7 **Li D**, Shimamura T, Ji H, Chen L, Haringsma HJ, McNamara K, Liang MC, Perera SA, Zaghlul S, Borgman CL, Kubo S, Takahashi M, Sun Y, Chirieac LR, Padera RF, Lindeman NI, Jänne PA, Thomas RK, Meyerson ML, Eck MJ, Engelman JA, Shapiro GI, Wong KK. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. *Cancer Cell* 2007; **12**: 81-93 [PMID: 17613438 DOI: 10.1016/j.ccr.2007.06.005]

8 **Engelman JA**, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, Shapiro GI, Nelson JM, Heymach JV, Meyerson M, Wong KK, Jänne PA. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. *Cancer Res* 2007; **67**: 11924-11932 [PMID: 18089823 DOI: 10.1158/0008-5472.CAN-07-1885]

9 **Li D**, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, Rettig WJ, Meyerson M, Solca F, Greulich H, Wong KK. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. *Oncogene* 2008; **27**: 4702-4711 [PMID: 18408761 DOI: 10.1038/onc.2008.109]

10 **Miller VA**, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y, Heo DS, Crino L, Tan EH, Chao TY, Shahidi M, Cong XJ, Lorence RM, Yang JC. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. *Lancet Oncol* 2012; **13**: 528-538 [PMID: 22452896 DOI: 10.1016/S1470-2045(12)70087-6]

11 **Jänne PA**, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. *N Engl J Med* 2015; **372**: 1689-1699 [PMID: 25923549 DOI: 10.1056/NEJMoa1411817]

12 **Jiang T**, Zhou C. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer. *Transl Lung Cancer Res* 2014; **3**: 370-372 [PMID: 25806323 DOI: 10.3978/j.issn.2218-6751.2014.08.02]

13 **Ramalingam SS**, Blackhall F, Krzakowski M, Barrios CH, Park K, Bover I, Seog Heo D, Rosell R, Talbot DC, Frank R, Letrent SP, Ruiz-Garcia A, Taylor I, Liang JQ, Campbell AK, O'Connell J, Boyer M. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. *J Clin Oncol* 2012; **30**: 3337-3344 [PMID: 22753918 DOI: 10.1200/JCO.2011.40.9433]

14 **Sequist LV**, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton K, Zacharchuk C, Freyman A, Powell C, Ananthakrishnan R, Quinn S, Soria JC. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. *J Clin Oncol* 2010; **28**: 3076-3083 [PMID: 20479403 DOI: 10.1200/JCO.2009.27.9414]

15 **Adams C**, Aldous DJ, Amendola S, Bamborough P, Bright C, Crowe S, Eastwood P, Fenton G, Foster M, Harrison TK, King S, Lai J, Lawrence C, Letallec JP, McCarthy C, Moorcroft N, Page K, Rao S, Redford J, Sadiq S, Smith K, Souness JE, Thurairatnam S, Vine M, Wyman B. Mapping the kinase domain of Janus Kinase 3. *Bioorg Med Chem Lett* 2003; **13**: 3105-3110 [PMID: 12941344 DOI: S0960894X03006577]

16 **Dallakyan S**, Olson AJ. Small-molecule library screening by docking with PyRx. *Methods Mol Biol* 2015; **1263**: 243-250 [PMID: 25618350 DOI: 10.1007/978-1-4939-2269-7\_19]

17 **Morris GM**, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *J Comput Chem* 2009; **30**: 2785-2791 [PMID: 19399780 DOI: 10.1002/jcc.21256]

18 **Pettersen EF**, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. UCSF Chimera--a visualization system for exploratory research and analysis. *J Comput Chem* 2004; **25**: 1605-1612 [PMID: 15264254 DOI: 10.1002/jcc.20084]

19 **Kleinschroth J,** Hartenstein J, Rudolph C, Schächtele C. Novel indolocarbazole protein kinase c inhibitors with improved biochemical and physicochemical properties. *Bioorg Med Chem Lett* 1995; **5**: 55-60 [DOI: 10.1016/0960-894X(94)00458-R]

20 **Lee HJ**, Schaefer G, Heffron TP, Shao L, Ye X, Sideris S, Malek S, Chan E, Merchant M, La H, Ubhayakar S, Yauch RL, Pirazzoli V, Politi K, Settleman J. Noncovalent wild-type-sparing inhibitors of EGFR T790M. *Cancer Discov* 2013; **3**: 168-181 [PMID: 23229345 DOI: 10.1158/2159-8290.CD-12-0357]

21 **Zhou W**, Ercan D, Chen L, Yun CH, Li D, Capelletti M, Cortot AB, Chirieac L, Iacob RE, Padera R, Engen JR, Wong KK, Eck MJ, Gray NS, Jänne PA. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. *Nature* 2009; **462**: 1070-1074 [PMID: 20033049 DOI: 10.1038/nature08622]


22 **Manning G**, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. *Science* 2002; **298**: 1912-1934 [PMID: 12471243]

23 **Young MA**, Shah NP, Chao LH, Seeliger M, Milanov ZV, Biggs WH, Treiber DK, Patel HK, Zarrinkar PP, Lockhart DJ, Sawyers CL, Kuriyan J. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. *Cancer Res* 2006; **66**: 1007-1014 [PMID: 16424036 DOI: 10.1158/0008-5472.CAN-05-2788]


24 **Modugno M**, Casale E, Soncini C, Rosettani P, Colombo R, Lupi R, Rusconi L, Fancelli D, Carpinelli P, Cameron AD, Isacchi A, Moll J. Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. *Cancer Res* 2007; **67**: 7987-7990 [PMID: 17804707 DOI: 10.1158/0008-5472.CAN-07-1825]

**P-Reviewer:** Rangel-Corona R, Zaravinos A, Zhang L **S-Editor:** Tian YL


**L-Editor: E-Editor:**




**Figure 1 JAK3 inhibitor VI selectively inhibits kinase activity of the EGFR gatekeeper mutant T790M/L858R *in vitro*.** Chemical structures of JAK3 inhibitor VI (A) and Gö7874 (B) are shown. C. Effects of JAK3 inhibitor VI on kinase activities of WT, L858R, and T790M/L858R EGFRs were compared. Recombinant EGFR kinase domains were treated using JAK3 inhibitor VI at 10 μmol/L, and phosphorylation was initiated by adding ATP in the presence of an artificial substrate peptide. Phosphorylation levels were measured by ELISA using an anti-phosphotyrosine antibody. Error bars indicate SEM (*n* = 4); a*P* < 0.05. NS: Not significant; EGFR: Epidermal growth factor receptor; JAK3: Janus kinase 3.



**Figure 2 JAK3 inhibitor VI reduces EGFR autophosphorylation in NCI-H1975 cells harboring EGFR T790M/L858R.** A-B: NCI-H1975 (A) or A431 (B) cells were treated with the indicated concentration of JAK3 inhibitor VI and were stimulated using 200 ng/mL EGF. Phosphorylation levels of EGFR Y1045 were analyzed using Western blotting. Phosphorylation levels of EGFR were normalized against total EGFR levels. Relative phosphorylation levels to the sample treated with DMSO and 200 ng/mL EGF are indicated. Right panels show the averages of relative phosphorylation levels from three independent experiments; C: NCI-H1975 cells were stimulated using 200 ng/mL EGF. Phosphorylation levels of STAT3 Y705 were analyzed using Western blotting; D: NCI-H1975 cells were treated using JAK3 inhibitor VI or JAK inhibitor I, as indicated. Phosphorylation levels of EGFR Y1068 and STAT3 Y705 were analyzed using Western blotting with phospho-specific antibodies. Error bars indicate SEM (*n* = 3); a*P* < 0.05. NS: Not significant; EGF (-): 0 ng/mL EGF; EGF (+): 200 ng/mL EGF; JAK3i (-): 0 μmol/L JAK3 inhibitor VI; JAK3i (+): 10 μmol/L JAK3 inhibitor VI; EGFR: Epidermal growth factor receptor; JAK3: Janus kinase 3.



**Figure 3 JAK3 inhibitor VI suppresses proliferation of NCI-H1975 cells.** A-B: NCI-H1975 (A) or A431 (B) cells were treated with JAK3 inhibitor VI, JAK inhibitor I, or gefitinib. Effects of indicated concentration of kinase inhibitors on cell proliferation were analyzed using the MTT assay; C: Effects of JAK3 inhibitor VI on proliferation were compared between NCI-H1975 and A549 cells using the MTT assay. Error bars indicate S.E.M. (*n* = at least 3); a*P* < 0.05. NS: Not significant; EGFR: Epidermal growth factor receptor; JAK3: Janus kinase 3.



**Figure 4 Structural analysis of JAK3 inhibitor VI binding to the EGFR T790M.** A: JAK3 inhibitor VI (cyan in EGFR WT, red in EGFR T790M/L858R, or yellow in JAK3) was modeled into EGFR WT, EGFR T790M/L858R (LRTM), or JAK3. A superimposed image is also shown (bottom right). The dotted lines indicate putative hydrogen bonds; B: Amino acid sequence alignments of EGFRs and JAKs, and BCR-ABL and Aurora kinases. Asterisk indicates the gatekeeper residues. EGFR: Epidermal growth factor receptor; JAK: Janus kinase; WT: Wild type.

**Table 1 List of kinase inhibitors used in a screening for compounds effective on EGFR T790M/L858R**

|  |  |
| --- | --- |
| **Target** | **Compound name** |
| AK | ABT-702 |
| AKT (PKB) | Akt Inhibitor IV, Akt Inhibitor VIII, Akt Inhibitor XI |
| AMPK | compound C |
| ATM | ATM/ATR kinase inhibitor, ATM kinase inhibitor |
| Aurora kinase | Aurora kinase/CDK inhibitor, aurora kinase inhibitor II, Aurora kinase inhibitor III |
| Bcr-abl | AG957 |
| BTK | LFM-A13, terreic acid |
| CAMKII | KN-93, KN-62, Lavendustin C |
| CDK | Kenpaullone, purvalanol A, Olomoucine, Alsterpaullone, Cdk1/2 inhibitor III, Cdk2/9 inhibitor, NU6102, Cdk4 inhibitor, NSC625987 |
| Chk | SB218078, Isogranulatimide, Chk2 inhibitor, Chk2 inhibitor II |
| CK | Ellagic acid　(dihydrate), TBB, DMAT, D4476 |
| Clk | TG003 |
| DGK | Diacylglycerol kinase inhibitor II |
| DNA-PK | IC60211 |
| eEF2 kinase | TX-1918 |
| EGFR | BPIQ-Ⅱ, AG1478, AG490 |
| FGFR | SU4984, SU5402 |
| Flt-3 | Flt-3 Inhibitor |
| Fms | cFMS Receptor Inhibitor |
| Fyn | SU6656 |
| GSK | GSK-3 inhibitor IX, 1-Azakenpaullone, Indirubin-3'-monoxime |
| HER2 | AG825 |
| IGF-IR | AG1024, AGL 2263 |
| IKK | BMS-345541, IKK-2 inhibitor VI |
| IRAK | IRAK-1/4 inhibitor |
| JAK | JAK Inhibitor I, JAK3 Inhibitor VI |
| JNK | SP600125, JNK inhibitor VIII |
| Lck | Damnacanthal, PP2 |
| MAPK | ERK inhibitor II |
| MEK | PD98059, U-0126, MEK inhibitor I |
| Met | SU11274 |
| MLCK | ML-7 |
| p38 MAPK | SB202190, SB239063 |
| PDGFR | AG1296, SU11652, PDGF receptor inhibitor V, PDGF receptor inhibitor IV |
| PI3K | LY-294002, Wortmannin |
| PKA | H-89, 4-cyano-3-methylisoquinoline |
| PKC | Bisindolymaleimide I, Go7874 |
| PKG | Rp-8-CPT-cGMPS, KT5823 |
| PKR | PKR inhibitor |
| Raf | RAF1 kinase inhibitor I, ZM 336372 |
| ROCK | H-1152, Y-27632 |
| Hsp90 | radicicol |
| Src | PP1 analog |
| Syk | Syk inhibitor |
| TGF-bRI | SB431542, TGF-beta RI kinase inhibitor II |
| Tpl2 | Tpl2 kinase inhibitor |
| TrKA | TrkA inhibitor |
| VEGFR | VEGFR receptor inhibitor II, VEGF recptor 2 inhibitor I, SU1498 |

AK: Adenosine kinase; AKT(PKB): Protein kinase B; AMPK: 5’-adenosine monophosphate-activated protein kinase; ATM: Ataxia telangiectasia mutated; Aurora: Aurora kinase; Bcr-abl: Breakpoint cluster region-Abelson fusion kinase; BTK: Bruton’s tyrosine kinase; CAMKII: Calcium/calmodulin-dependent protein kinase II; CDK: Cyclin-dependent kinase; Chk: Checkpoint kinase; CK: Casein kinase; Clk: Cdc2-like kinase; DGK: Diacylglycerol kinase; DNA-PK: DNA-dependent protein kinase; eEF2 kinase: Eukaryotic elongation factor 2 kinase; EGFR: Epidermal growth factor receptor; FGFR: Fibroblast growth factor receptor; Flt-3: Fms-related tyrosine kinase 3; Fms: Feline McDonough sarcoma (Colony-stimulating factor-1 Receptor); GSK: Glycogen synthase kinase; HER2: Human epidermal growth factor receptor 2; IGF-IR: Insulin-like Growth Factor I receptor; IKK: IκB kinase; IRAK: Interleukin-1 receptor-associated kinase; JAK: Janus kinase; JNK: Jun N-terminal Kinase; Lck: Lymphocyte-specific protein tyrosine kinase; MAPK: Mitogen activated protein kinase; MEK: Mitogen-activated Protein/Extracellular signal-regulated Kinase Kinase; MLCK: Myosin light chain kinase; p38 MAPK: P38 mitogen-activated protein kinase; PDGFR: Platelet-derived growth factor receptor; PI3K: Phosphatidylinositol-4-Kinase; PKA: Protein kinase A; PKC: Protein kinase C; PKG: Protein kinase G; PKR: Double-stranded RNA-activated protein kinase; Raf: Rapidly accelerated fibrosarcoma; ROCK: Rho-associated protein kinase; Hsp90: Heat shock protein; Syk: Spleen tyrosine kinase; TGF-bRI: Transforming growth factor-beta type I receptor; Tpl2: Tumor progression locus 2; TrKA: Tyrosine Kinase Receptor A (Tyrosine Kinase Receptor for nerve growth factor); VEGFR: Vascular endothelial growth factor receptor.